# Senti Biosciences Holdings, Inc.: financial statements, quarterly

SNTI · Nasdaq · CIK 1854270 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/snti.md) · [Financials](/companies/snti/financials.md) · [Filings](/companies/snti/filings.md) · [Insiders](/companies/snti/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/snti/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.3](/filings/0001854270-24-000116.md) | [0.0 d](/filings/0001854270-25-000042.md) | [0.0](/filings/0001854270-24-000052.md) | [0.0](/filings/0001854270-24-000101.md) | [0.0](/filings/0001854270-24-000116.md) | [0.0 d](/filings/0001628280-26-021580.md) | [0.0](/filings/0001628280-26-035126.md) | [0.0](/filings/0001628280-26-057110.md) | not reported | not reported | [0.0](/filings/0001628280-26-035126.md) | [0.0](/filings/0001628280-26-057110.md) |
| Research and development | $m | [9.1](/filings/0001854270-24-000116.md) | [9.1 d](/filings/0001854270-25-000042.md) | [8.8](/filings/0001854270-25-000065.md) | [9.2](/filings/0001854270-25-000090.md) | [8.7](/filings/0001628280-25-052125.md) | [7.8 d](/filings/0001628280-26-021580.md) | [9.3](/filings/0001628280-26-035126.md) | [10.0](/filings/0001628280-26-057110.md) | [10.5](/filings/0001628280-25-052125.md) | [7.8 d](/filings/0001628280-26-021580.md) | [5.3](/filings/0001628280-26-035126.md) | [7.8](/filings/0001628280-26-057110.md) |
| Operating income | $m | [(43.9)](/filings/0001854270-24-000116.md) | [(18.7) d](/filings/0001854270-25-000042.md) | [(16.3)](/filings/0001854270-25-000065.md) | [(13.4)](/filings/0001854270-25-000090.md) | [(15.2)](/filings/0001628280-25-052125.md) | [(16.2) d](/filings/0001628280-26-021580.md) | [(16.4)](/filings/0001628280-26-035126.md) | [(16.8)](/filings/0001628280-26-057110.md) | [(16.9)](/filings/0001628280-25-052125.md) | [(18.6) d](/filings/0001628280-26-021580.md) | [(4.6)](/filings/0001628280-26-035126.md) | [(14.5)](/filings/0001628280-26-057110.md) |
| Income tax | $m | [0.0](/filings/0001854270-24-000116.md) | not reported | [0.0](/filings/0001854270-25-000065.md) | [0.0](/filings/0001854270-25-000090.md) | [0.0](/filings/0001628280-25-052125.md) | [0.0 d](/filings/0001628280-26-021580.md) | [0.0](/filings/0001628280-26-035126.md) | [0.0](/filings/0001628280-26-057110.md) | [0.0](/filings/0001628280-25-052125.md) | [0.0 d](/filings/0001628280-26-021580.md) | [0.0](/filings/0001628280-26-035126.md) | [0.0](/filings/0001628280-26-057110.md) |
| Net income | $m | [(14.9)](/filings/0001854270-24-000116.md) | [(71.1)](/filings/0001854270-24-000029.md) | [(12.1)](/filings/0001628280-25-052125.md) | [(11.2)](/filings/0001628280-25-052125.md) | [(28.9)](/filings/0001628280-25-052125.md) | [(0.6) d](/filings/0001628280-26-021580.md) | [(14.1)](/filings/0001628280-26-057110.md) | [(14.7)](/filings/0001628280-26-057110.md) | [(18.1)](/filings/0001628280-25-052125.md) | [(14.5) d](/filings/0001628280-26-021580.md) | [(4.2)](/filings/0001628280-26-057110.md) | [(12.8)](/filings/0001628280-26-057110.md) |
| Diluted EPS | $ per share | [(3.36)](/filings/0001854270-24-000116.md) | not reported | [(2.65)](/filings/0001854270-25-000065.md) | [(2.45)](/filings/0001854270-25-000090.md) | [(6.31)](/filings/0001628280-25-052125.md) | not reported | [(1.41)](/filings/0001628280-26-035126.md) | [(0.56)](/filings/0001628280-26-057110.md) | [(0.69)](/filings/0001628280-25-052125.md) | not reported | [(0.14)](/filings/0001628280-26-035126.md) | [(0.41)](/filings/0001628280-26-057110.md) |
| Basic EPS | $ per share | [(3.36)](/filings/0001854270-24-000116.md) | not reported | [(2.65)](/filings/0001854270-25-000065.md) | [(2.45)](/filings/0001854270-25-000090.md) | [(6.31)](/filings/0001628280-25-052125.md) | not reported | [(1.41)](/filings/0001628280-26-035126.md) | [(0.56)](/filings/0001628280-26-057110.md) | [(0.69)](/filings/0001628280-25-052125.md) | not reported | [(0.14)](/filings/0001628280-26-035126.md) | [(0.41)](/filings/0001628280-26-057110.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [39.4](/filings/0001854270-24-000116.md) | [35.9](/filings/0001854270-25-000042.md) | [23.7](/filings/0001854270-24-000052.md) | [15.9](/filings/0001854270-24-000101.md) | [10.5](/filings/0001854270-24-000116.md) | [48.3](/filings/0001628280-26-021580.md) | [33.8](/filings/0001854270-25-000065.md) | [21.6](/filings/0001854270-25-000090.md) | [12.2](/filings/0001628280-25-052125.md) | [16.4](/filings/0001628280-26-057110.md) | [8.9](/filings/0001628280-26-035126.md) | [6.5](/filings/0001628280-26-057110.md) |
| Current assets | $m | [79.0](/filings/0001854270-23-000129.md) | [71.2](/filings/0001854270-25-000042.md) | [55.7](/filings/0001854270-24-000052.md) | [44.3](/filings/0001854270-24-000101.md) | [17.4](/filings/0001854270-24-000116.md) | [59.0](/filings/0001628280-26-021580.md) | [45.2](/filings/0001854270-25-000065.md) | [32.5](/filings/0001854270-25-000090.md) | [18.2](/filings/0001628280-25-052125.md) | [23.3](/filings/0001628280-26-057110.md) | [14.8](/filings/0001628280-26-035126.md) | [13.0](/filings/0001628280-26-057110.md) |
| Total assets | $m | [132](/filings/0001854270-23-000129.md) | [119](/filings/0001854270-25-000042.md) | [102](/filings/0001854270-24-000052.md) | [86.9](/filings/0001854270-24-000101.md) | [57.7](/filings/0001854270-24-000116.md) | [97.8](/filings/0001628280-26-021580.md) | [82.8](/filings/0001854270-25-000065.md) | [68.5](/filings/0001854270-25-000090.md) | [52.7](/filings/0001628280-25-052125.md) | [51.2](/filings/0001628280-26-057110.md) | [38.2](/filings/0001628280-26-035126.md) | [33.1](/filings/0001628280-26-057110.md) |
| Current liabilities | $m | [10.1](/filings/0001854270-23-000129.md) | [12.7](/filings/0001854270-25-000042.md) | [9.6](/filings/0001854270-24-000052.md) | [9.1](/filings/0001854270-24-000101.md) | [9.1](/filings/0001854270-24-000116.md) | [13.1](/filings/0001628280-26-021580.md) | [10.7](/filings/0001854270-25-000065.md) | [10.0](/filings/0001854270-25-000090.md) | [12.0](/filings/0001628280-25-052125.md) | [14.0](/filings/0001628280-26-057110.md) | [14.3](/filings/0001628280-26-035126.md) | [15.8](/filings/0001628280-26-057110.md) |
| Total liabilities | $m | [48.8](/filings/0001854270-23-000129.md) | [52.6](/filings/0001854270-25-000042.md) | [46.1](/filings/0001854270-24-000052.md) | [42.8](/filings/0001854270-24-000101.md) | [41.7](/filings/0001854270-24-000116.md) | [47.1](/filings/0001628280-26-021580.md) | [44.9](/filings/0001854270-25-000065.md) | [43.9](/filings/0001854270-25-000090.md) | [44.6](/filings/0001628280-25-052125.md) | [45.6](/filings/0001628280-26-057110.md) | [35.7](/filings/0001628280-26-035126.md) | [36.5](/filings/0001628280-26-057110.md) |
| Shareholders' equity | $m | [82.9](/filings/0001854270-24-000116.md) | [66.9](/filings/0001628280-26-021580.md) | [56.1](/filings/0001628280-25-052125.md) | [44.1](/filings/0001628280-25-052125.md) | [16.0](/filings/0001628280-25-052125.md) | [25.6](/filings/0001628280-26-057110.md) | [37.9](/filings/0001628280-26-057110.md) | [24.7](/filings/0001628280-26-057110.md) | [8.1](/filings/0001628280-25-052125.md) | [5.6](/filings/0001628280-26-057110.md) | [2.6](/filings/0001628280-26-057110.md) | [(3.4)](/filings/0001628280-26-057110.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(15.4) d](/filings/0001854270-24-000116.md) | [(7.0) d](/filings/0001854270-25-000042.md) | [(11.7)](/filings/0001854270-25-000065.md) | [(8.3) d](/filings/0001854270-25-000090.md) | [(7.9) d](/filings/0001628280-25-052125.md) | [(13.5) d](/filings/0001628280-26-021580.md) | [(14.1)](/filings/0001628280-26-035126.md) | [(13.1) d](/filings/0001628280-26-057110.md) | [(9.4) d](/filings/0001628280-25-052125.md) | [(6.9) d](/filings/0001628280-26-021580.md) | [(7.5)](/filings/0001628280-26-035126.md) | [(14.2) d](/filings/0001628280-26-057110.md) |
| Capital expenditure | $m | [1.9 d](/filings/0001854270-24-000116.md) | [0.0 d](/filings/0001854270-25-000042.md) | [0.0](/filings/0001854270-25-000065.md) | [0.0 d](/filings/0001854270-25-000090.md) | [0.0 d](/filings/0001628280-25-052125.md) | [0.0 d](/filings/0001628280-26-021580.md) | [0.0](/filings/0001854270-25-000065.md) | [0.2 d](/filings/0001628280-26-057110.md) | [0.0 d](/filings/0001628280-25-052125.md) | [0.0 d](/filings/0001628280-26-021580.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [43.4](/filings/0001854270-23-000129.md) | [44.1](/filings/0001854270-24-000052.md) | [4.4](/filings/0001854270-24-000101.md) | [4.4](/filings/0001854270-24-000116.md) | [4.6](/filings/0001854270-25-000065.md) | [4.6](/filings/0001854270-25-000090.md) | [4.6](/filings/0001628280-25-052125.md) | [10.0](/filings/0001628280-26-035126.md) | [26.1](/filings/0001628280-26-057110.md) | [26.2](/filings/0001628280-25-052125.md) | [31.0](/filings/0001628280-26-035126.md) | [31.1](/filings/0001628280-26-057110.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 31,144,754 at 2026-07-31, from the cover of the [10-Q filed 2026-08-14](/filings/0001628280-26-057110.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.